scholarly journals A novel interaction between fibroblast growth factor receptor 3 and the p85 subunit of phosphoinositide 3-kinase: activation-dependent regulation of ERK by p85 in multiple myeloma cells

2009 ◽  
Vol 18 (11) ◽  
pp. 1951-1961 ◽  
Author(s):  
L. Salazar ◽  
T. Kashiwada ◽  
P. Krejci ◽  
P. Muchowski ◽  
D. Donoghue ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor Receptor ◽  
Growth Factor Receptor ◽  
Fibroblast Growth ◽  
Myeloma Cells ◽  
Kinase Activation ◽  
Phosphoinositide 3 Kinase

Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma

Blood ◽  
2001 ◽  
Vol 97 (3) ◽  
pp. 729-736 ◽  
Author(s):  
Marta Chesi ◽  
Leslie A. Brents ◽  
Sarah A. Ely ◽  
Carlos Bais ◽  
Davide F. Robbiani ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Growth Factor ◽  
Tumor Progression ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor Receptor ◽  
Growth Factor Receptor ◽  
Fibroblast Growth ◽  
Myeloma Cells ◽  
Activating Mutations ◽  
Nih 3T3

Abstract The t(4;14) translocation occurs frequently in multiple myeloma (MM) and results in the simultaneous dysregulated expression of 2 potential oncogenes, FGFR3 (fibroblast growth factor receptor 3) from der(14) and multiple myeloma SET domain protein/Wolf-Hirschhorn syndrome candidate gene 1 from der(4). It is now shown that myeloma cells carrying a t(4;14) translocation express a functional FGFR3 that in some cases is constitutively activated by the same mutations that cause thanatophoric dysplasia. As with activating mutations of K-ras and N-ras, which are reported in approximately 40% of patients with MM, activating mutations ofFGFR3 occur during tumor progression. However, the constitutive activation of ras and FGFR3 does not occur in the same myeloma cells. Thus the activated forms of these proteins appear to share an overlapping role in tumor progression, suggesting that they also share the signaling cascade. Consistent with this prediction, it is shown that activated FGFR3—when expressed at levels similar to those seen in t(4;14) myeloma—is an oncogene that acts through the MAP kinase pathway to transform NIH 3T3 cells, which can then generate tumors in nude mice. Thus,FGFR3, when overexpressed in MM, may be not only oncogenic when stimulated by FGF ligands in the bone marrow microenvironment, but is also a target for activating mutations that enable FGFR3to play a ras-like role in tumor progression.

scholarly journals NF449 Is a Novel Inhibitor of Fibroblast Growth Factor Receptor 3 (FGFR3) Signaling Active in Chondrocytes and Multiple Myeloma Cells

2010 ◽  
Vol 285 (27) ◽  
pp. 20644-20653 ◽  
Author(s):  
Pavel Krejci ◽  
Shunichi Murakami ◽  
Jirina Prochazkova ◽  
Lukas Trantirek ◽  
Katarina Chlebova ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor Receptor ◽  
Growth Factor Receptor ◽  
Fibroblast Growth ◽  
Myeloma Cells

Mutation, SNP, and isoform analysis of fibroblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patients

Blood ◽  
2003 ◽  
Vol 102 (2) ◽  
pp. 772-773 ◽  
Author(s):  
Obiageli N. Onwuazor ◽  
Xiao-Yan Wen ◽  
Ding-Yan Wang ◽  
Lihua Zhuang ◽  
Esther Masih-Khan ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor Receptor ◽  
Growth Factor Receptor ◽  
Fibroblast Growth ◽  
Newly Diagnosed

scholarly journals CHIR-258 Is Efficacious in A Newly Developed Fibroblast Growth Factor Receptor 3–Expressing Orthotopic Multiple Myeloma Model in Mice

2006 ◽  
Vol 12 (16) ◽  
pp. 4908-4915 ◽  
Author(s):  
Xiaohua Xin ◽  
Tinya J. Abrams ◽  
Paul W. Hollenbach ◽  
Katherine G. Rendahl ◽  
Yan Tang ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor Receptor ◽  
Growth Factor Receptor ◽  
Fibroblast Growth
Sign in / Sign up

Export Citation Format

Share Document